Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice

Summary

The co-stimulatory immune molecule CD40L figures prominently in a variety of inflammatory conditions including arterial disease. Recently, we made the surprising finding that CD40L mediates atherogenesis independently of its classic receptor CD40 via a novel interaction with the leukocyte integrin Mac-1. Here, we hypothesised that selective blockade of the CD40L-Mac-1 interaction may also retard restenosis. We induced neointima formation in C57/BL6 mice by ligation of the left carotid artery. Mice were randomised to daily intraperitoneal injections of either cM7, a small peptide selectively inhibiting the CD40L-Mac-1 interaction, scM7, a scrambled control peptide, or saline for 28 days. Interestingly, cM7-treated mice developed neointima of similar size compared with mice receiving the control peptide or saline as assessed by computer-assisted analysis of histological cross sections. These data demonstrate that the CD40L-Mac-1 interaction is not required for the development of restenosis. In contrast, CD40-deficient mice subjected to carotid ligation in parallel, developed significantly reduced neointimal lesions compared with respective wild-type controls (2872 ± 843 µm² vs 35469 ± 11870 µm²). Flow cytometry in CD40-deficient mice revealed reduced formation of platelet-granulocyte and platelet-inflammatory monocyte-aggregates. In vitro, supernatants of CD40-deficient platelet-leukocyte aggregates attenuated proliferation and increased apoptosis of smooth muscle cells. Unlike in the setting of atherosclerosis, CD40L mediates neointima formation via its classic receptor CD40 rather than via its recently described novel interaction with Mac-1. Therefore, selective targeting of CD40L-Mac-1 binding does not appear to be a favorable strategy to fight restenosis.

Keywords

Inflammation - CD40L - CD40 - Mac-1 - restenosis - neointima formation - mice

• References

• 1 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 2 Donners MM, Daemen MJ, Cleutjens KB, Heeneman S. Inflammation and restenosis: implications for therapy. Ann Med 2003; 35: 523-531.
• 3 Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology 2011; 217: 521-532.
• 4 Gerdes N, Zirlik A. Co-stimulatory molecules in and beyond co-stimulation – tipping the balance in atherosclerosis?. Thromb Haemost 2011; 106: 804-813.
• 5 Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
• 6 Mach F, Schonbeck U, Sukhova GK. et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931-1936.
• 7 Chai H, Aghaie K, Zhou W. Soluble CD40 ligand induces human coronary artery smooth muscle cells proliferation and migration. Surgery 2009; 146: 5-11.
• 8 Lutgens E, Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002; 12: 27-32.
• 9 Mukundan L, Milhorn DM, Matta B. et al. CD40-mediated activation of vascular smooth muscle cell chemokine production through a Src-initiated, MAPK-dependent pathway. Cell Signal 2004; 16: 375-384.
• 10 Hristov M, Gumbel D, Lutgens E. et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation. 2010 121. 315-32401/06.
• 11 Li G, Sanders JM, Bevard MH. et al. CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury. Am J Pathol 2008; 172: 1141-1152.
• 12 Yan JC, Ding S, Liang Y. et al. Relationship between upregulation of CD40 system and restenosis in patients after percutaneous coronary intervention. Acta pharmacologica Sinica 2007; 28: 339-343.
• 13 Donners MM, Beckers L, Lievens D. et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111: 4596-4604.
• 14 Song Z, Jin R, Yu S. et al. Crucial Role of CD40 Signaling in Vascular Wall Cells in Neointimal Formation and Vascular Remodeling After Vascular Interventions. Arterioscler Thromb Vasc Biol 2012; 32: 50-64.
• 15 Song Z, Jin R, Yu S. et al. CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One 2011; 06: e23239.
• 16 Stachon P, Missiou A, Walter C. et al. Tumor necrosis factor receptor associated factor 6 is not required for atherogenesis in mice and does not associate with atherosclerosis in humans. PLoS One 2010; 05: e11589.
• 17 Lutgens E, Lievens D, Beckers L. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
• 18 Leveille C, Bouillon M, Guo W. et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem 2007; 282: 5143-5151.
• 19 Zirlik A, Maier C, Gerdes N. et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115: 1571-1580.
• 20 Wolf D, Hohmann JD, Wiedemann A. et al. Binding of CD40L to Mac-1’s I-do-main involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circ Res 2011; 109: 1269-1279.
• 21 Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology 2012; 217: 521-532.
• 22 Wang Y, Sakuma M, Chen Z. et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation 2005; 112: 2993-3000.
• 23 Inoue T, Kato T, Hikichi Y. et al. Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening. Thromb Haemost 2006; 95: 43-48.
• 24 Inoue T, Sakai Y, Morooka S. et al. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996; 28: 1127-1133.
• 25 Inoue T, Uchida T, Yaguchi I. et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003; 107: 1757-1763.
• 26 Neumann FJ, Ott I, Gawaz M. et al. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996; 27: 819-824.
• 27 Simon DI, Dhen Z, Seifert P. et al. Decreased neointimal formation in Mac-1(−/−) mice reveals a role for inflammation in vascular repair after angioplasty. J Clin Invest 2000; 105: 293-300.
• 28 Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol 1997; 17: 2238-2244.
• 29 Hilgendorf I, Eisele S, Remer I. et al. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 1991-1999.
• 30 Missiou A, Rudolf P, Stachon P. et al. TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation. Circ Res 2010; 107: 757-766.
• 31 Lonsdorf AS, Kramer BF, Fahrleitner M. et al. Engagement of alphaIIbbeta3 (GPIIb/IIIa) with alphanubeta3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. J Biol Chem 2012; 287: 2168-2178.
• 32 Willecke F, Zeschky K, Ortiz Rodriguez A. et al. Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS One 2011; 06: e19405.
• 33 Wolf D, Jehle F, Ortiz Rodriguez A. et al. CD40L deficiency attenuates diet-induced adipose tissue inflammation by impairing immune cell accumulation and production of pathogenic IgG-antibodies. PLoS One 2012; 07: e33026.
• 34 Andre P, Prasad KS, Denis C V. et al. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med 2002; 08: 247-252.
• 35 Kawai T, Andrews D, Colvin RB. et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 06: 114.
• 36 Hermann A, Schror K, Weber AA. CD40 ligand (CD40L) does not stimulate proliferation of vascular smooth muscle cells. Eur J Cell Biol 2002; 81: 213-221.
• 37 Remskar M, Li H, Chyu KY. et al. Absence of CD40 signaling is associated with an increase in intimal thickening after arterial injury. Circ Res 2001; 88: 390-394.
• 38 Eslin DE, Zhang C, Samuels KJ. et al. Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004; 104: 3173-3180.
• 39 Cerletti C, Tamburrelli C, Izzi B. et al. Platelet-leukocyte interactions in thrombosis. Thromb Res 2012; 129: 263-266.
• 40 King SM, McNamee RA, Houng AK. et al. Platelet dense-granule secretion plays a critical role in thrombosis and subsequent vascular remodeling in atherosclerotic mice. Circulation 2009; 120: 785-791.
• 41 Inwald DP, McDowall A, Peters MJ. et al. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-1048.
• 42 Henn V, Steinbach S, Buchner K. et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054.
• 43 Pakala R, Willerson J T, Benedict CR. Mitogenic effect of serotonin on vascular endothelial cells. Circulation 1994; 90: 1919-1926.
• 44 Hodivala-Dilke KM, McHugh KP, Tsakiris DA. et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999; 103: 229-238.
• 45 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 08: 1227-1234.